JP Patent

JP5693239B2 — ４−ピリジノン化合物および癌についてのその使用

Assigned to Bristol Myers Squibb Co · Expires 2015-04-01 · 11y expired

What this patent protects

Patent listed against tazemetostat-hydrobromide.

Drugs covered by this patent

Patent Metadata

Patent number
JP5693239B2
Jurisdiction
JP
Classification
—
Expires
2015-04-01
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.